China's Online Dermatological Drugs Market Hits CN¥ 5.69B as E-Prescriptions Reshape Channel Mix

Executive Summary

China's online dermatological drugs market reached CN¥ 5.69 billion in 2023 (+2.8% YoY), with January-July 2024 accelerating to +20.4% YoY as e-prescription policies and growing consumer comfort with online pharmaceutical purchases reshape the channel landscape^[1]. The global dermatological drugs market is projected to reach US$ 71.66 billion by 2029 (9.67% CAGR), while China's domestic market hit CN¥ 25.7 billion in 2023, with the online share tripling from 7.5% to 17.9% over five years. This analysis examines the market's structural transformation, platform dynamics, and the emerging RX opportunity that is redefining pharmaceutical e-commerce in China.

Online Channel Triples Its Share in Five Years

China's online dermatological drug channel grew from CN¥ 1.5 billion (7.5% of total) in 2018 to CN¥ 4.6 billion (17.9%) in 2023, a compound annual growth rate of approximately 25%^[1]. Projections indicate online sales will reach CN¥ 8.9 billion (26.5% of total) by 2027, confirming that the inflection point in pharmaceutical e-commerce has passed.

The offline channel maintained modest growth from CN¥ 18.6 billion to CN¥ 21.1 billion over the same period, indicating that online growth captures both incremental demand and redistributes existing purchases. For pharmaceutical companies, this demands a dual-channel strategy: maintaining offline pharmacy presence while investing heavily in e-commerce capabilities.

China's dermatological drug market online channel share tripled from 7.5% in 2018 to 17.9% in 2023, projected to reach 26.5% by 2027

The RX Prescription Opportunity

Prescription drug share rose to 28.7% in January-July 2024, up from 27.4% in 2023^[1]. This trend is driven by government prescription outflow policies redirecting prescriptions from hospital pharmacies to retail and online channels, and growing acceptance of online prescribing for chronic dermatological conditions such as eczema, psoriasis, and atopic dermatitis.

The full-year 2023 market reached CN¥ 5.69 billion with 119 million units sold, while January-July 2024 alone hit CN¥ 3.86 billion (+20.4% YoY), signaling continued acceleration. The +20.4% growth -- a sharp increase from the +2.8% recorded in full-year 2023 -- suggests that a new wave of online pharmaceutical adoption is underway.

Prescription drug share rises to 28.7% in Jan-Jul 2024, driven by e-prescription policy enablement

Platform Dynamics: JD.com Surges, Douyin Enters

The channel landscape reveals a dramatic divergence in growth trajectories^[1]:

• JD.com (京东): Achieved +50% YoY growth in both RX and OTC segments through its "JD Health Pharmacy" model, self-operated offline pharmacies, and "JD Buy Medicine in One Hour" delivery
• Taobao/Tmall (淘系): Maintains the largest market share but shows deceleration, with RX sales declining -2.1% YoY
• Douyin (抖音): OTC business surging +98.5% YoY, demonstrating content-driven pharmaceutical marketing is viable

JD.com achieves +50% YoY growth in both RX and OTC, while Douyin OTC surges +98.5% YoY

Cross-border Drugs Reach CN¥ 370 Million

The cross-border dermatological drugs segment reached CN¥ 370 million in January-July 2024 (+12% YoY), with sales peaking in spring-summer months^[1]. Anti-hair-loss products (minoxidil brands Rogaine and Bailleul) and mosquito-bite relief products (MUHI) dominate the cross-border landscape across both Tmall Global and JD.com International.

This growing cross-border demand signals consumer willingness to seek products not yet registered domestically, creating opportunity for international pharmaceutical companies targeting the Chinese market.